Nama's AI scorecard currently rates AbCellera Biologics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ABCL report earnings?

AbCellera Biologics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.18.

What is the ABCL price target?

The median analyst price target from 12 analysts is $16.00, with a range of $9.00 – $30.00.

Is ABCL Shariah compliant?

Nama's AAOIFI-style screen reads AbCellera Biologics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

AbCellera Biologics (ABCL)

Healthcare · Biotechnology · NASDAQ

AbCellera Biologics (ABCL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.85B and a free-cash-flow yield of -4.9%. Over the most recent reported fiscal year, revenue grew 160.6%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +183.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-29.2%

How far the last close sits under the highest price of the past five years.

Market cap	$3.85B
Trailing P/E	—
Price / book	4.1
Price / sales	59.4
FCF yield	-4.9%
Dividend yield	—
Gross margin	-198.9%
Operating margin	-1550.0%
Net margin	-248.8%
Revenue growth (YoY)	+160.6%
Revenue growth (3-yr annual)	-46.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ABCL earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.18). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 5, 2026	-$0.18	-$0.16	-12.5%	$4.05M
Q1 2026	May 11, 2026	-$0.14	-$0.20	+30.0%	$8.31M
Q4 2025	Feb 24, 2026	-$0.03	-$0.18	+83.3%	$44.85M
Q3 2025	Nov 6, 2025	-$0.19	-$0.16	-18.8%	$8.96M

ABCL analyst price target

Median target $16.00 from 12 analysts, ranging $9.00 – $30.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ABCL data on Nama Insights →

ABCL FAQ

Is ABCL a buy?: Nama's AI scorecard currently rates AbCellera Biologics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ABCL report earnings?: AbCellera Biologics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.18.
What is the ABCL price target?: The median analyst price target from 12 analysts is $16.00, with a range of $9.00 – $30.00.
Is ABCL Shariah compliant?: Nama's AAOIFI-style screen reads AbCellera Biologics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.